tetano
Editor, Senior Moderator
Vaccine
. 2023 Oct 24:S0264-410X(23)01175-1.
doi: 10.1016/j.vaccine.2023.10.005. Online ahead of print. Quadrivalent neuraminidase RNA particle vaccine protects pigs against homologous and heterologous strains of swine influenza virus infection
Pravina Kitikoon[SUP] 1 [/SUP], Susan M Knetter[SUP] 2 [/SUP], Mark A Mogler[SUP] 3 [/SUP], Chandra L Morgan[SUP] 2 [/SUP], Allison Hoehn[SUP] 2 [/SUP], Supraja Puttamreddy[SUP] 3 [/SUP], Erin L Strait[SUP] 4 [/SUP], Ruud P A M Segers[SUP] 5 [/SUP]
Affiliations
Influenza A virus in swine (IAV-S) continues to cause significant negative impact to both sows and growing pigs. The viral hemagglutinin (HA) and neuraminidase (NA) genes continue to evolve with HA diversifying at a faster rate than NA. Depending on country, whole inactivated virus (WIV) commercial and autogenous vaccines, as well as veterinary prescription vaccines targeting HA, are currently available. The use of these vaccines is focused on reducing virus and clinical signs in sows and to provide HA-specific maternally derived antibodies (MDA) to their suckling pigs. The deficiency in this strategy is that HA-MDA does not persist long enough to protect pigs through their growing phase from infection, and HA-MDA can interfere with effective pig immunization. This study evaluated the immunogenicity and efficacy of an adjuvanted, quadrivalent RNA Particle vaccine (Sequivity NA), currently licensed as Sequivity® IAV-S NA. This vaccine was formulated based on four NA antigens representing the major NA clades of IAV subtypes H1N1, H1N2 and H3N2 circulating in swine herds in the United States. In a series of trials, pigs were vaccinated twice, at three days and three weeks of age (WOA), followed by challenge with either homologous or heterologous IAV strains at 8 or 15 WOA. The Sequivity NA vaccine induced robust serum NA inhibition (NI) antibody and protected against IAV-S strains with homologous and heterologous NA to that of the vaccine. The magnitude and duration of nasal shedding was reduced in vaccinated-pigs challenged with either homologous or heterologous virus within the same NA clade. This NA-based RNA Particle vaccine avoids the known impact of HA-MDA on pig vaccination and provides a new tool to successfully reduce IAV-induced disease in the pig population.
Keywords: Influenza; Neuraminidase; Neuraminidase inhibition; RNA particle; RNA vaccine; Replicon particle; Swine; Vaccine.
. 2023 Oct 24:S0264-410X(23)01175-1.
doi: 10.1016/j.vaccine.2023.10.005. Online ahead of print. Quadrivalent neuraminidase RNA particle vaccine protects pigs against homologous and heterologous strains of swine influenza virus infection
Pravina Kitikoon[SUP] 1 [/SUP], Susan M Knetter[SUP] 2 [/SUP], Mark A Mogler[SUP] 3 [/SUP], Chandra L Morgan[SUP] 2 [/SUP], Allison Hoehn[SUP] 2 [/SUP], Supraja Puttamreddy[SUP] 3 [/SUP], Erin L Strait[SUP] 4 [/SUP], Ruud P A M Segers[SUP] 5 [/SUP]
Affiliations
- PMID: 37884412
- DOI: 10.1016/j.vaccine.2023.10.005
Influenza A virus in swine (IAV-S) continues to cause significant negative impact to both sows and growing pigs. The viral hemagglutinin (HA) and neuraminidase (NA) genes continue to evolve with HA diversifying at a faster rate than NA. Depending on country, whole inactivated virus (WIV) commercial and autogenous vaccines, as well as veterinary prescription vaccines targeting HA, are currently available. The use of these vaccines is focused on reducing virus and clinical signs in sows and to provide HA-specific maternally derived antibodies (MDA) to their suckling pigs. The deficiency in this strategy is that HA-MDA does not persist long enough to protect pigs through their growing phase from infection, and HA-MDA can interfere with effective pig immunization. This study evaluated the immunogenicity and efficacy of an adjuvanted, quadrivalent RNA Particle vaccine (Sequivity NA), currently licensed as Sequivity® IAV-S NA. This vaccine was formulated based on four NA antigens representing the major NA clades of IAV subtypes H1N1, H1N2 and H3N2 circulating in swine herds in the United States. In a series of trials, pigs were vaccinated twice, at three days and three weeks of age (WOA), followed by challenge with either homologous or heterologous IAV strains at 8 or 15 WOA. The Sequivity NA vaccine induced robust serum NA inhibition (NI) antibody and protected against IAV-S strains with homologous and heterologous NA to that of the vaccine. The magnitude and duration of nasal shedding was reduced in vaccinated-pigs challenged with either homologous or heterologous virus within the same NA clade. This NA-based RNA Particle vaccine avoids the known impact of HA-MDA on pig vaccination and provides a new tool to successfully reduce IAV-induced disease in the pig population.
Keywords: Influenza; Neuraminidase; Neuraminidase inhibition; RNA particle; RNA vaccine; Replicon particle; Swine; Vaccine.